Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0062-2489; OpenAlex author ID A5100346128. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 16

  1. Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer. Last author DOI 10.1080/15384047.2026.2699508↗
  2. Pancreatic cancer EMT‑targeted therapy: Molecular mechanisms and clinical translation (Review). Last author DOI 10.3892/ijo.2026.5867↗
  3. CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. Last author DOI 10.1002/ctm2.70501↗
  4. N6-Methylandenosine-related lncRNAs as potential biomarkers for predicting prognosis and the immunotherapy response in pancreatic cancer. Last author DOI 10.1007/s00018-024-05573-w↗
  5. Circular RNA LIPH promotes pancreatic cancer glycolysis and progression through sponge miR-769-3p and interaction with GOLM1. Last author DOI 10.1002/ctm2.70003↗
  6. Exosomal lncRNA LINC01268 promotes pancreatic cancer progression via the miR-217-KIF2A-PI3K/AKT axis. Last author DOI 10.1016/j.gendis.2022.12.018↗
  7. NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. Last author DOI 10.1093/carcin/bgac102↗
  8. LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer. Last author DOI 10.1007/s12672-022-00522-0↗
  9. Identification of prognostic immune-related lncRNAs in pancreatic cancer. Last author DOI 10.3389/fimmu.2022.1005695↗
  10. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy. Co-author DOI 10.3389/fimmu.2022.863346↗
  11. Circular RNAs as novel potential biomarkers for pancreatic cancer. Last author DOI 10.7150/jca.58640↗
  12. Evolving trends in pancreatic cancer therapeutic development. First author DOI 10.21037/apc.2019.09.01↗
  13. Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis. Last author DOI 10.18632/oncotarget.15148↗
  14. Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mc.22023↗
  15. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010. Last author DOI 10.1038/srep06747↗
  16. MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. Co-author DOI 10.1007/s12038-011-9083-4↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaomeng He · 7 shared papers, 2022–2025 · strength 1.28
  2. Shanshan Liu · 4 shared papers, 2022–2023 · strength 0.63
  3. Zhihui Bai · 3 shared papers, 2022–2025 · strength 0.58
  4. Jianqing Xu · 3 shared papers, 2017–2025 · strength 0.46
  5. Yan Ma · 3 shared papers, 2022–2023 · strength 0.46
  6. Li Xu · 2 shared papers, 2024–2025 · strength 0.41
  7. Feng Shen · 1 shared paper, 2026 · strength 0.39
  8. Mengting Luo · 1 shared paper, 2026 · strength 0.39
  9. Di Yang · 2 shared papers, 2022–2025 · strength 0.37
  10. Zhengyi Xie · 1 shared paper, 2026 · strength 0.32
  11. Guirui Zhang · 1 shared paper, 2026 · strength 0.32
  12. Wenchuan Wu · 1 shared paper, 2025 · strength 0.22
  13. Imani Bijou · 1 shared paper, 2019 · strength 0.20
  14. Yan Ma · 1 shared paper, 2024 · strength 0.19
  15. Shanshan Liu · 1 shared paper, 2021 · strength 0.17
  16. Yanfang Liu · 1 shared paper, 2022 · strength 0.16
  17. Jianming Zheng · 1 shared paper, 2022 · strength 0.16
  18. Xiaoyan Zhang · 1 shared paper, 2023 · strength 0.15
  19. Subrata Sen · 2 shared papers, 2011–2014 · strength 0.10
  20. Zenglin Pei · 1 shared paper, 2017 · strength 0.06
  21. Dong Yan · 1 shared paper, 2017 · strength 0.06
  22. Huanhuan Sun · 1 shared paper, 2014 · strength 0.06
  23. Jinyun Chen · 1 shared paper, 2014 · strength 0.04
  24. Qian Liu · 1 shared paper, 2014 · strength 0.04
  25. Ann McNeill Killary · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.